NCT01907477已完成不适用
Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 2
- 主要终点
- the variability of protein profiles
研究概览
简要总结
The aim of the present work is to study the protein expressions profiles of neutropenic patients (with a high risk of invasive mycosis) who developed - versus who did not develop invasive mycosis (principally aspergillosis and candidosis) in order to identify biomarkers for the diagnosis, prognosis and /or prediction of invasive mycosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Patients with malignant haemopathy who received chemotherapy likely to lead to severe neutropenia (PN<500/mm3) for a foreseeable period of 10 days.
- •Patients aged 14 years or older (no upper age limit)
- •Patients with malignant haemopathy who received an autologous marrow graft.
- •Patients with severe idiopathic medullar aplasia (PN<500/mm3) who need to be hospitalised for at least 10 days consecutively (with or without immunosuppressant treatment).
- •Patients who have provided written informed consent to participate in this study.
排除标准
- •Patients who received an allograft of marrow or hematopoietic stem cell transplant (given that these patients carry a risk of aspergillosis, which in most cases appears after medullar recovery, they will not be included in the study).
- •Patients who received an autologous hematopoietic stem cell transplant (given that the duration of the neutropenia is often less than 10 days).
- •Patients who do not meet the inclusion criteria
- •Persons not covered by the national Health Insurance Agency
研究组 & 干预措施
neutropenic patients
Other
干预措施: Samples taken at the clinical hematology unit (Other)
结局指标
主要结局
the variability of protein profiles
时间窗: baseline
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Biomarkers to Predict and Monitor Response to InfliximabCrohn DiseaseNCT04655729Massachusetts General Hospital120
进行中（未招募）
不适用
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting PrognosisPlaque RuptureAcute Coronary SyndromesNCT06763835Xuebo Liu301
已完成
不适用
Men Undergoing Radical ProstatectomyProstate CancerNCT00582530Memorial Sloan Kettering Cancer Center513
Unknown
不适用
Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart FailureHeart FailureNCT03727828Shanghai 10th People's Hospital3,000
尚未招募
不适用
Multiomic Analysis of Serum in Acute Period of Traumatic Brain InjuryTraumatic Brain InjuryNCT05867992RenJi Hospital80